Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Tempus AI
Study ID
NCT07756034
Status
Recruiting
Apply to this trial

Conditions

  • Cancer
  • Hematologic Malignancies
  • Pediatric Acute Myeloid Leukemia
  • Solid Tumor Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Study Details

This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus. Olivia will serve as the primary interface for eConsent and enrollment into the registry. The platform will also help create a retrospective and prospective registry by working with over 1,000 healthcare systems to combine electronic health records (EHR) and Patient Reported Outcomes (PROs) in a single spot. There may be sub-studies as an add-on to this parent protocol. The sub-studies will address specific goals of the targeted research activities and will usually include additional information specific to each research study.

Key Dates

First listed
Aug 10, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Jul 31, 2031
Completion
Jul 31, 2031

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Substudy OLV002: Pediatric Acute Myeloid Leukemia (pAML)
    Prospective, decentralized, participant/caregiver-mediated data registry for real-world evidence generation in pediatric AML. This is a minimal-risk, observational registry focused on pAML- intentional data collection (i.e., surveys/PROs), and associated evidence generation. Pediatric patients with confirmed AML diagnosis (eg, consented and authorized patients with completed laboratory test results and/or confirmed cancer diagnoses) in the United States. Pediatric subject's parent/legally authorized representative will consent for their participation and inclusion into the registry.

Primary Outcome Measure

Completeness and Yield of Multi-Modal Real-World Data Capture [ Time Frame: Through study completion, up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Tempus AIChicagoIllinois60654
Mark Shapiro
[email protected]
833-514-4187
Mark Shapiro (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
Tempus AI· Chicago, IL

Related Studies